A Study to Evaluate Subjects With Turner Syndrome Treated With Growth Hormone

Characterization of Subjects With Turner Syndrome Treated With Growth Hormone in the National Cooperative Growth Study (NCGS)

This study is a multicenter, open-label, observational, postmarketing surveillance study of Genentech growth hormone (GH) products in the treatment of girls with Turner syndrome in the United States and Canada.

Inclusion Criteria:

• Are girls with Turner syndrome who are being or will be treated with Nutropin, Nutropin AQ, or Protropin
• Are willing to keep follow-up appointments throughout study participation
• Are girls with Turner syndrome who have submitted Form 4 upon discontinuation and may also submit Form 9

Exclusion Criteria:

• Have Noonan syndrome
• Subjects treated within the last 6 months with a non-Genentech GH preparation
• Have closed epiphyses prior to NCGS enrollment
• Have active neoplasia